Registration and Continental Breakfast

8:00 a.m.

Welcome and Opening Remarks

8:15 a.m.

Kidney Paired Donation (KPD): One Year Post the United Network for Organ Sharing (UNOS) Pilot, Jeffrey L. Veale, MD, University of California, Los Angeles (UCLA)
In the United States, the number of patients on the deceased-donor waiting list now exceeds 88,000. KPD facilitates additional donations of living-donor kidneys, allowing for a significant increase in the number of patients that receive a living kidney transplant, which, in turn frees up additional deceased donor kidneys for those that are on the national wait list for a kidney. UNOS, the governing body for organ allocation in the United States, has developed a pilot program with the eventual goal of consolidating KPD across all U.S. kidney-transplant programs. This presentation will provide an update of the UNOS pilot and discuss the challenges faced and the next steps that will need to be initiated to maximize the potential benefit for patients who might receive transplants as a result of broadened KPD.

9:15 a.m.

Liver Transplantation for Malignant Disease, John A. Goss, MD, FACS, Baylor College of Medicine, St. Luke's Cooley Transplant Center, and Texas Children's Hospital
For many patients with malignant diseases of the liver, liver transplantation offers the only opportunity for cure or palliation. As a result of organ scarcity, patients are selected on the basis of tumor stage. This presentation will review the importance of patient selection in predicting outcomes in relation to transplantation for hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, metastatic neuroendocrine tumors, secondary solid tumors and other rare malignancies. The Milan criteria for hepatocellular carcinoma will also be discussed.

10:15 a.m.

Break

10:30 a.m.

Pharmaceuticals in Transplantation, Rebecca L. Corey, PharmD, BCPS, Mayo Clinic Phoenix
Organ transplant immunosuppression is complex. Tremendous advances have been witnessed in this arena over the past 50 years, and enhanced therapeutic strategies have been associated with improved patient and graft survival rates. However, risks and adverse effects associated with long-term immunosuppression remain of great concern, and the consequence of the administration of these agents presents a number of challenges to clinicians. Treatment regimens need to be tailored to meet the individual patient’s characteristics and to balance the risks and benefits of these medications. This presentation will provide an overview of the immunosuppressive agents used in organ transplant; the comorbidities and adverse effects associated with these agents, and the necessity for variance in immunosuppressive regimens. Optimal management of these patients will also be discussed.

11:30 a.m.

Treatment of Intestinal Failure: Rehabilitation and Transplantation, David Mercer, MD, PhD, FRCS(C), University of Nebraska Medical Center
Intestinal failure is a highly disabling condition, and its diagnosis is life changing for both patients and their families. Although it is not uniformly fatal, if not properly managed, it could lead to serious, life-threatening complications. This presentation will present case studies on the optimal management of intestinal failure, including rehabilitation and transplantation.

12:15 p.m.

Lunch (provided)

1:15 p.m.

Transition of Congenital Heart Disease (CHD) Patients to Adulthood, John L. Jefferies, MD, MPH, FAAP, FACC, Cincinnati Children's Hospital
Medical and surgical breakthroughs over the past few decades have dramatically improved outcomes for children with CHD. When these patients reach adulthood, they can benefit from transitioning into an adult program that’s designed to meet their evolving needs. This presentation will discuss the challenges of this transition and the importance of providing uninterrupted, coordinated care between pediatric and adult providers, as well as outline management strategies to assist in this transition.

2:00 p.m.

Management of Ventricular Assist Devices, Michael Petty, PhD, RN, CCNS, CNS, University of Minnesota Medical Center, Fairview
As the population of patients supported with long-term implantable left ventricular assist devices (LVADs) has grown, patient selection, operative technique, and patient management strategies have been refined, leading to improved outcomes. Managing patients on chronic LVAD support requires regular patient follow-up, multidisciplinary care teams, and frequent laboratory and echocardiographic surveillance to ensure optimal outcomes. This presentation will review management strategies to reduce morbidity and mortality in heart failure patients supported chronically with LVADs, and describe candidate selection, outpatient strategies to optimize device performance and heart failure management. It will also review important device complications that warrant close outpatient monitoring.

3:00 p.m.

Break

3:15 p.m.

The Evolution of Lung Transplantation in the Adult Population, Michael Petty, PhD, RN, CCNS, CNS, University of Minnesota Medical Center, Fairview
Over the past 25 years, lung transplantation has become a viable and accepted treatment option for patients with end-stage lung disease. The major limiting factor to the number of transplants being performed is donor lung shortage. Research suggests that double-lung transplants have a long-term advantage over single lung transplants, more than doubling the recipient’s chances of extending his or her life by over a decade. The finding is potentially controversial, researchers say, because there is already a shortage of organ donors, and more widespread use of bilateral lung transplants could nearly halve the potential number of beneficiaries. While the number of single-lung transplants performed annually has remained stable, the number of bilateral transplants has consistently increased and has surpassed the number of single lung transplants. This presentation will provide an overview of the evolution and advances in lung transplant and will address the advantages of double- versus single-lung transplantation and when this should be considered.

4:00 p.m.

Ethical Issues in Liver Transplantation, John P. Roberts, MD, FACS, University of California, San Francisco (UCSF) Medical Center
Liver transplantation is standard therapy for patients with end-stage liver disease. Advances in surgical techniques, immunosuppression, and organ preservation, have led to increased survival for both deceased-donor-liver- and living-donor-liver-transplants (LDLT). The demand for donor organs, however, vastly exceeds the supply. As a result, there are more than 1,800 deaths per year among those on the liver transplant waiting list. The relative shortage of donor organs provides the basis for many of the ethical issues associated with liver transplantation. This presentation will discuss ethical issues surrounding liver transplantation, such as LDLT—including the trade-offs between whether left-lobe donation, which is safer for the donor but poses more recipient risk, is better than right-lobe donation, which has more donor risk but less recipient risk; ethical concerns surrounding liver transplant for patients with acute alcoholic hepatitis and weighing the acceptable risk of the recipient’s return to alcohol; obesity; and nonalcoholic steatohepatitis (NASH) and the risk of its recurrence.

5:00–7:00 p.m.

COMPLIMENTARY GET-ACQUAINTED RECEPTION
Join your colleagues for hors d’oeuvres and beverages. You won’t want to miss this opportunity to gather information and ideas from exhibitors regarding the management of complex medical conditions.

Continental Breakfast

8:00 a.m.

Welcome and Opening Remarks

8:15 a.m.

An Overview of Stem Cell Transplantation (SCT), C. Frederick LeMaistre, MD, Sarah Cannon Cancer Services
As the field of SCT continues to grow and evolve, managing the continuum of care for these patients can be a unique challenge for clinicians. With increased emphasis on outpatient care, cost containment and the demand for quality, health care professionals look for guidelines that will facilitate achievement of optimal outcomes. This presentation will review key concepts of SCT, as well as the different sources, types and indications for SCT.

9:15 a.m.

National Marrow Donor Program (NMDP): Strategies to Increase the Stem Cell Transplant Registry and Numbers Projected by 2020, Navneet Majhail, MD, MS, National Marrow Donor Program
The number of allogeneic SCTs performed worldwide continues to increase. In addition, the characteristics of patients, donors, and selected treatments are changing. This presentation will address strategies being implemented by the NMDP to increase the SCT registry and preview what is projected to occur by 2020.

10:00 a.m.

Break

10:15 a.m.

Graft-Versus-Host Disease (GVHD): Chronic and Acute, Scott Solomon, MD, Northside Hospital
GVHD is the most serious and common long-term complication of allogeneic hematopoietic stem cell transplantation (HSCT). Recognizing chronic GVHD and distinguishing it from other comorbid conditions can be challenging. This presentation will review risk factors for developing chronic GVHD, common clinical presentations and principles for managing chronic GVHD

11:15 a.m.

Current Management of Prostate Cancer: Assisting Consumers in Making Informed Decisions, Thomas Schwaab, MD, PhD, Roswell Park Cancer Institute
Prostate cancer is a leading cause of cancer deaths in men. Some prostate cancers are slow-growing and may not need definitive treatment, while others are aggressive and will require treatment by one or more of the currently available modalities. This presentation will compare and contrast current approaches and emerging clinical data for the screening, diagnosis and treatment of clinically localized cancer of the prostate and describe the current management of prostate cancer, including ways to assist consumers in making informed decisions about definitive treatment so that these decisions reflect both clinical reality and their personal needs and values.

12:15 p.m.

LUNCHEON PRESENTATION—An Overview of OptumHealth Care Solutions (optional)
OptumHealth features best-in-class programs and services in case management, disease management, treatment of complex medical conditions, decision support, physical medicine and wellness. Learn about the products and services available through OptumHealth that can help payers and employers aggressively manage costs while enhancing members’/employees’ health and well-being.

1:30 p.m.

Hematopoietic Stem Cell Transplant (HSCT) for Autoimmune Disease in Adults, Richard K. Burt, MD, Northwestern University Feinberg School of Medicine
The term autoimmune diseases encompasses a spectrum of diseases whose clinical manifestations and, possibly, biological features vary widely. The results of conventional treatment are considered unsatisfactory in aggressive forms of autoimmune disease, with subsets of patients having short life expectancies. Data have supported the hypothesis that autologous HSCT can alter disease progression in severe autoimmune disease, and, relying on expanding scientific evidence, some research groups have used autologous HSCT in the most disabling autoimmune diseases with the aim of resetting the patient’s immune system. This presentation will review the role of HSCT for autoimmune disease in adults.

2:30 p.m.

Multiple Myeloma Update, Hien Duong, MD, Taussig Cancer Institute, Cleveland Clinic
The survival of patients with multiple myeloma has significantly increased over the past decade, mainly due to the efficacy of novel agents. Advances in the development of multiple myeloma drugs have had a profound impact on the way the disease is treated. Studies are being conducted to determine whether they may be as effective as, or possibly even more effective than, a stem cell transplant. This presentation will provide an update on the best current options for the treatment of multiple myeloma.

3:15 p.m.

Break

3:30 p.m.

The Fundamentals of Clinical Trials, Sudha R. Pavuluri Quamme, MD, University of Wisconsin
Clinical trials have become the gold-standard scientific method for the evaluation of pharmaceuticals, biologics, devices, procedures and diagnostic tests. This trial design has been successfully used in both therapeutic approaches and disease prevention. This presentation will review the design, analysis and phases of a clinical trial that must take place to determine its effects on clinical practice.

4:15–5:00 p.m.

Successful SCT for Adolescent and Young Adult (AYA) Patients: Challenges in Diagnosis, Treatment, and Survivorship, Kenneth R. Cooke, MD, Rainbow Babies and Children’s Hospital
The number of AYA patients with cancer who require SCT procedures continues to grow. Unfortunately, this subset of patients has not experienced improvements in outcomes enjoyed by younger and older patient populations. Understanding the unique medical and psychosocial challenges that affect the AYA oncology population is critical for optimal diagnosis, treatment, and long-term survivorship in the pre- and post-transplant periods. This presentation will review details regarding the complexities surrounding the diagnosis and treatment of malignant disorders in AYA patients, as well as discuss the unique short- and long-term medical and psychosocial issues facing AYA patients requiring SCT.

Continental Breakfast

8:00 a.m.

Welcome and Opening Remarks

8:15 a.m.

Breast Cancer: What’s New in Treatment and Research? Naoto T. Ueno, MD, PhD, FACP, The University of Texas MD Anderson Cancer Center
Despite huge strides during the past 20 years in the diagnosis and management of breast cancer, learning that one has this condition is still frightening and often confusing to patients. A variety of factors are used to determine the treatment plan for patients with recurrent, advanced or metastatic breast cancer. This presentation will review what is new in breast cancer research, including information on risk factors and the rapidly expanding treatment options currently available.

9:00 a.m.

Advances in the Management of Melanoma, Thomas F. Gajewski, MD, PhD, The University of Chicago Medical Center
Melanoma can occur anywhere on the skin or the nails, even on mucosal surfaces and in the eye. The most powerful weapons against melanoma are prevention and early detection. However, in the case of advanced disease, the treatment paradigms are changing rapidly. This presentation will provide an update on malignant melanoma, including the latest treatment strategies that show great promise for improving outcomes.

9:45 a.m.

Break

10:00 a.m.

Chronic Myelogenous Leukemia (CML): Treatment and Monitoring, Jerald P. Radich, MD, Fred Hutchinson Cancer Research Center
Over the past decade, promising new therapies have revolutionized the treatment of CML. However, significant challenges to the achievement of optimal outcomes still remain. This presentation will compare and contrast the treatment modalities currently available for CML.

10:45 a.m.

Beyond Cancer Treatment: Navigating the Path of Cancer Survivorship, Anita Y. Kinney, PhD, RN, Huntsman Cancer Institute at the University of Utah
Survivorship issues for cancer patients are of growing importance as advances in the detection and treatment of cancer have increased. Cancer survivors need assistance navigating the varied and complex issues they often face after treatment. This presentation will review approaches to the management of cancer survivors that are aimed at maximizing the quality of life of this rapidly growing group of individuals.

11:30 a.m.

Lunch (provided)

12:30 p.m.

Cancer Pain Management: Finding the Best Treatment for Patients, Karen Stanley, RN, MSN, AOCN, FAAN, Nursing Consultant, Cancer Care
Optimal supportive care for the cancer patient requires an interdisciplinary approach that encompasses pain management, end-of-life issues and psychological support. This presentation will describe the etiology of cancer-related pain and address the importance of pain management to help relieve or prevent suffering and improve patients’ quality of life. It will also explore palliative care and end-of-life issues for patients and their families.

1:30 p.m.

HSCT for Pediatric Solid Tumors, Leslie E. Lehmann, MD, Dana-Farber Cancer Institute/Children’s Hospital Boston
While advances in the treatment of pediatric cancers have increased cure rates, children with metastatic or recurrent solid tumors still have a dismal prognosis despite initial transient responses to therapy. HSCT is frequently used to treat patients with other high-risk diseases, such as Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms’ tumor, retinoblastoma, germ-cell tumors, lymphomas and brain tumors. This presentation will discuss the evolving role of HSCT for the treatment of pediatric solid tumors.

2:15 p.m.

Break

2:30 p.m.

What’s New and Promising in Treatment Options for Malignant Brain Tumors, John B. Fiveash, MD, UAB Comprehensive Cancer Center
Treatment of brain cancer is more complex than the treatment of some other cancers. The prognosis depends not only on the type, grade, and size of the tumor, but on its location in the brain. This presentation will address the different types of brain tumors, as well as treatment modalities and prognosis for these patients.

3:15–4:00 p.m.

Genetic Insights on Hereditary Cancers, James M. Ford, MD, Stanford University School of Medicine
Individuals differ in their inherited tendency to develop cancer. Major single-gene defects that cause early cancer onset have been known for many years from their inheritance patterns, and inherited defects that have weaker effects on predisposition were also suspected to exist. This presentation will provide a framework for understanding the frequency of inherited mutations and the consequences of these mutations for increased predisposition to cancer.